STOCK TITAN

Caribou Biosciences (CRBU) Stock Price, News & Analysis

CRBU NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
54 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-45.6% close of October 7, 2026
1-year change
-83.8% closing prices, November 20, 2025 to November 20, 2026
1-month change
-45.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing cell therapies for patients with devastating diseases, particularly hematologic malignancies. The company applies its genome-editing platform, including Cas12a chRDNA (CRISPR hybrid RNA-DNA) technology, to create allogeneic, or off-the-shelf, CAR-T cell therapies that are designed to be manufactured in advance from healthy donors and available for rapid treatment and broad patient access.

Business focus and therapeutic area

According to the company’s disclosures, Caribou’s work centers on genome-edited cell therapies for oncology. Its allogeneic CAR-T product candidates are directed at established cell surface targets where autologous CAR-T therapies have already shown clinical proof of concept, specifically CD19 and B cell maturation antigen (BCMA). The company uses its chRDNA technologies to introduce multiple genome edits intended to “armor” its cell therapies, including checkpoint disruption and immune cloaking strategies, to potentially enhance activity against blood cancers.

Core pipeline and product candidates

Caribou is advancing two lead clinical-stage allogeneic CAR-T cell therapy programs for hematologic malignancies:

  • Vispacabtagene regedleucel (vispa-cel; formerly CB-010) – an allogeneic anti-CD19 CAR-T cell therapy being evaluated in adults with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL), including second-line large B cell lymphoma (2L LBCL), in the multicenter, open-label ANTLER phase 1 clinical trial.
  • CB-011 – an allogeneic anti-BCMA CAR-T cell therapy being evaluated in adults with relapsed or refractory multiple myeloma (r/r MM) in the multicenter, open-label CaMMouflage phase 1 clinical trial.

Both vispa-cel and CB-011 are described by the company as off-the-shelf CAR-T therapies intended to provide rapid treatment and broad access for patients with hematologic malignancies.

Vispacabtagene regedleucel (vispa-cel) and the ANTLER trial

Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy being studied in the ANTLER phase 1 trial for patients with r/r B-NHL, including 2L LBCL. To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The U.S. Food and Drug Administration (FDA) has granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL.

In ANTLER, patients receive a lymphodepletion regimen of cyclophosphamide and fludarabine followed by a single dose of vispa-cel. The trial has included dose escalation, dose expansion, and a confirmatory cohort using a partial HLA matching strategy between donor and patient. Company-reported data describe an 84-patient safety dataset and analyses of a 22-patient confirmatory cohort and a 35-patient optimized profile cohort of CD19‑naïve LBCL patients, with reported overall response rates and complete response rates and a generally well-tolerated safety profile that allowed outpatient administration at both academic centers and sophisticated community hospitals.

CB-011 and the CaMMouflage trial

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy in the CaMMouflage phase 1 trial for adults with r/r MM who have received three or more prior lines of therapy. To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic engineered with an immune cloaking strategy that combines a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. CB-011 has received Fast Track and Orphan Drug designations from the FDA.

In the dose escalation portion of CaMMouflage, CB-011 has been evaluated at multiple CAR-T cell dose levels and under two different lymphodepletion regimens based on cyclophosphamide and fludarabine. Company communications describe responses across dose levels in heavily pretreated, fourth-line and later multiple myeloma patients, and identify a single-dose 450 million CAR-T cell regimen with a specified lymphodepletion schedule as the recommended dose for expansion.

Genome-editing platform and technology

Caribou describes itself as a CRISPR genome-editing biopharmaceutical company. Its platform includes Cas12a chRDNA technology, which the company states enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. The platform is used to implement multiple genome-editing strategies in its allogeneic CAR-T cell products, including PD-1 disruption in vispa-cel and immune cloaking edits in CB-011.

Regulatory designations and clinical-stage status

The company emphasizes that it is in the clinical stage, with its lead programs in phase 1 trials. Vispa-cel has RMAT, Orphan Drug, and Fast Track designations for B-NHL, and CB-011 has Fast Track and Orphan Drug designations for r/r MM. Caribou has also reported interactions with the FDA regarding a planned randomized, controlled pivotal phase 3 trial of vispa-cel in 2L LBCL CD19-naïve patients who are ineligible for transplant and autologous CAR-T therapy, with progression-free survival as a planned primary endpoint.

Business model and operations

Caribou’s disclosures indicate that it operates as a clinical-stage biopharmaceutical company focused on developing a pipeline of allogeneic CAR-T cell therapies. Its product candidates are manufactured in advance from healthy donor T cells, with the goal of enabling broad patient access, shorter time to treatment, and increased manufacturing scale compared to autologous approaches. The company has also reported licensing and collaboration revenue in its financial updates, reflecting arrangements related to its technologies.

Exchange listing and compliance

Caribou Biosciences’ common stock trades on the Nasdaq Global Select Market under the ticker symbol CRBU. An 8-K dated June 18, 2025, reports that the company received a compliance notice from Nasdaq indicating it had regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum closing bid price of $1.00 per share.

Company status

Recent press releases and Form 8-K filings describe ongoing clinical development, financial reporting, and participation in healthcare and biopharma investor conferences. There is no indication in the provided materials of bankruptcy, liquidation, merger completion, or delisting from Nasdaq.

Stock Performance

$0.2843
-8.44%
-0.0262
Last updated: at
-83.8%
Performance 1 year
$30.7M
108.0M
Shares outstanding As of November 2, 2026.

Caribou Biosciences (CRBU) closed at $0.2843 on November 20, 2026. Over the past 12 months, the price has lost 83.8%.

See what a $1,000 investment in CRBU would be worth today

Average down calculator for CRBU

CRBU Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Caribou Biosciences generated $11.2M in revenue in FY2025, operating income reached -$148.3M, and net income was -$148.1M. Diluted earnings per share stood at -$1.59. The company generated -$111.0M in operating cash flow. The current ratio was 5.71, measuring current assets divided by current liabilities.

$11.2M
Revenue (FY2025)
-$148.1M
Net Income (FY2025)
-$111.0M
Operating Cash Flow

Upcoming Events

DEC
12
December 12, 2026 - December 15, 2026 Clinical

ASH 2026 Presentations

Three presentations (two oral, one poster) in New Orleans on vispa-cel (ANTLER) and CB-011 (CaMMouflage) data at ASH 2026.
H2
2027
H2 2027 Financial

Cash runway into 2H 2027

Management expects cash to fund operations through second half of 2027

Caribou Biosciences has 2 upcoming scheduled events. The next event, "ASH 2026 Presentations", is scheduled for December 12, 2026 (in 20 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the CRBU stock price.

Short Interest History

Last 12 Months

Short interest in Caribou Biosciences (CRBU) currently stands at 14.9 million shares, up 18.6% from the previous reporting period, representing 15.0% of the float. Since November 2025, short interest has increased by 142.5%.

Days to Cover History

Last 12 Months

Days to cover for Caribou Biosciences (CRBU) currently stands at 6.0 days, up 292.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.5 to 13.1 days.

CRBU Company Profile & Sector Positioning

Caribou Biosciences (CRBU) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CRBU often look at related companies in the same sector, including Rein Therapeutics, Inc. (RNTX), Veru Inc. (VERU), Actinium Pharmaceuticals, Inc (ATNM), Kalaris Therapeutics, Inc. (KLRS), and NextCure, Inc. (NXTC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRBU's relative position within its industry.

Frequently Asked Questions

The current stock price of Caribou Biosciences (CRBU) is $0.2843 as of November 20, 2026.

The market cap of Caribou Biosciences (CRBU) is approximately $30.7M. Learn more about what market capitalization means .

The FY2025 revenue of Caribou Biosciences (CRBU) is $11.2M, from its most recent completed fiscal year.

The FY2025 net income of Caribou Biosciences (CRBU) is -$148.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Caribou Biosciences (CRBU) is -$1.59 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Caribou Biosciences (CRBU) is -$111.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Caribou Biosciences (CRBU), current assets divided by current liabilities, was 5.71 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Caribou Biosciences (CRBU) is -$148.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing allogeneic, off-the-shelf CAR-T cell therapies for patients with devastating diseases, particularly hematologic malignancies such as B cell non-Hodgkin lymphoma and multiple myeloma.

Caribou’s lead product candidates are vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.

Caribou uses a genome-editing platform that includes Cas12a chRDNA technology to introduce precise edits into donor-derived T cells. These edits are used to armor its allogeneic CAR-T therapies through strategies such as PD-1 knockout in vispa-cel and an immune cloaking approach in CB-011 involving B2M knockout and a B2M–HLA-E fusion protein.

Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T cell therapy being evaluated in the ANTLER phase 1 clinical trial for adults with relapsed or refractory B cell non-Hodgkin lymphoma, including second-line large B cell lymphoma. It incorporates a PD-1 knockout edit and has received RMAT, Orphan Drug, and Fast Track designations from the FDA for B-NHL.

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being studied in the CaMMouflage phase 1 trial for adults with relapsed or refractory multiple myeloma who have received three or more prior lines of therapy. It incorporates an immune cloaking strategy with B2M knockout and a B2M–HLA-E fusion protein and has Fast Track and Orphan Drug designations from the FDA.

In its filings, Caribou states that its allogeneic CAR-T therapies, manufactured in advance from healthy donors, are intended to offer broad patient access, shorter time to treatment with an off-the-shelf product, significantly lower manufacturing costs, and a smaller manufacturing footprint compared to autologous CAR-T therapies. For CB-011, the company also cites a single-dose regimen and potential differences in infection rates and immune recovery compared to bispecific antibody therapies.

ANTLER is a multicenter, open-label phase 1 clinical trial evaluating vispa-cel in adults with relapsed or refractory B cell non-Hodgkin lymphoma. It includes dose escalation, dose expansion, and a confirmatory cohort that prospectively evaluates partial HLA matching between donor and patient, with patients receiving a single dose of vispa-cel after lymphodepletion with cyclophosphamide and fludarabine.

CaMMouflage is a multicenter, open-label phase 1 clinical trial evaluating CB-011 in adults with relapsed or refractory multiple myeloma who have been treated with three or more prior lines of therapy. The trial uses a 3+3 dose escalation design with multiple CAR-T cell dose levels and different lymphodepletion regimens and is proceeding toward a dose expansion phase at a selected dose and regimen.

Caribou Biosciences’ common stock is listed on the Nasdaq Global Select Market under the ticker symbol CRBU.

An 8-K dated June 18, 2025, reports that Caribou received a compliance notice from Nasdaq stating that the company had regained compliance with Nasdaq Listing Rule 5450(a)(1) after its common stock maintained a minimum closing bid price of $1.00 per share for the required period.